Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2010-09-28
2011-10-18
Blumel, Benjamin P (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
Reexamination Certificate
active
08039004
ABSTRACT:
The present invention relates to monoparamunity inducers based on paramunizing viruses or viral components of a myxomavirus strain from rabbits with typically generalizing disease, to a method for the production thereof and to the use thereof as medicaments for the regulatory optimization of the paramunizing activities for the prophylaxis and therapy of various dysfunctions in humans and animals.
REFERENCES:
patent: 4717723 (1988-01-01), Sugden
patent: 6340462 (2002-01-01), Paoletti
patent: 6805870 (2004-10-01), Mayr
patent: 7494799 (2009-02-01), Mayr
patent: 7691391 (2010-04-01), Mayr
patent: 2003/0013190 (2003-01-01), Mayr
patent: 2003/0119782 (2003-06-01), Cham
patent: 2004/0175398 (2004-09-01), Moyer
patent: 2006/0147419 (2006-07-01), Perera et al.
patent: 2008/0213307 (2008-09-01), Mayr
patent: 2008/0267920 (2008-10-01), Mayr
patent: 2008/0305129 (2008-12-01), Mayr
patent: 2011/0020908 (2011-01-01), Mayr et al.
patent: 0669133 (1995-08-01), None
patent: 0 972 840 (2004-05-01), None
patent: WO 95/22978 (1995-08-01), None
patent: WO 01/74386 (2001-10-01), None
patent: WO 2004/078206 (2004-09-01), None
Mossman, K. et al., Myxoma Virus M-T7 a Secreted Homolog of the Interferon-y Receptor, Is a Critical Virulence I-Actor for the Development of Myxomatosis in European Rabbits,' Virology, vol. 215, Article No. 0003, pp. 17-30, (1996).
Upton, C. et al., “Myxoma Virus Expresses a Secreted Protein with Homology to the Tumor Necrosis Factor Receptor Gene Family that Contributes to Viral Virulence,” Virology, vol. 184, pp. 370-382, (1991).
Saito, J. K. et al., “Attenuation of the Myxoma Virus and Use of the Living Attenuated Virus as an Immunizing Agent for Myxomatosis,” The Journal of Infectious Diseases, vol. 114, pp. 417-428, (Dec. 1964).
McCabe, V. J. et al., “Vaccination of Cats with an Attenuated Recombinant Myxoma Virus Expressing Feline Caticivirus Capsid Protein,” Vaccine, vol. 20, pp. 2454-2462, (2002).
Nash, R et al., “Immunomodulation by Viruses: The Myxoma Virus Story,” Immunological Reviews, vol. 168, pp. 103-120, (1999).
Mayr, A. et al., “A New Concept in Prophylaxis and Therapy: Paramunization by Poxvirus Inducers,” Pesq. Vet. Bras., vol. 19, No. 3/4, pp. 91-98, (Jul. 1999).
Buttner, M., Principles of Paramunization: Option and Limits in Veterinary Medicine, Comp. Immun. Microbiol. Infect. Dis., vol. 16, No. 1, pp. 1-10, (1993).
Macen et al., Expression of the Myxoma Virus Tumor Necrosis Factor Receptor Homologoue and M11L Genes Is Required to Prevent Virus-Induced Apoptosis in Infected Rabbit T Lymphocytes, Virology 218:2, 1996.
Kerr et al., Immune Responses to Myxoma Virus, Viral Immunology 15:229-246 (2002).
Cameron et al., The Complete DNA Sequence of Myxoma Virus, Virology 264:298-318 (1999).
Ogino et al., Cell Fusion Activities of Hantaan Virus Evelope Glycoproteins, J. Virology 78:10776-10782 (2004).
Mayr Anton
Mayr Barbara
Bavarian Nordic A/S
Blumel Benjamin P
Law Office of Salvatore Arrigo and Scott Lee, LLP
LandOfFree
Methods of preparing myxomavirus compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of preparing myxomavirus compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of preparing myxomavirus compositions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4296547